Several clinical programs in the global peptide and oligonucleotide (TIDES) space have recently reported progress, spanning functional cure of chronic hepatitis B, long-term weight management for obesity, metabolic dysfunction-associated steatohepatitis (MASH), and cardiometabolic diseases. A number of these studies have reached Phase 2b or Phase 3.
BRII-B (02137) announced positive Phase 2b results for its hepatitis B small interfering RNA (siRNA) therapy elebsiran in combination with immunotherapy. Some patients maintained hepatitis B surface antigen (HBsAg) clearance 24 weeks after the end of treatment.
Gan&Lee Pharmaceuticals. (603087.SH) reported positive topline results from the Phase 3b GRADUAL-3 study of its investigational GLP-1 receptor agonist bofanglutide (GZR18) in adults with obesity or overweight. The study met its primary endpoint, showing that after prior weight loss treatment, reducing the dosing frequency of bofanglutide to once monthly still effectively maintained the achieved weight reduction.
During the 2026 American Association for the Study of Liver Diseases Liver Meeting, Merck (MRK.US) disclosed Phase 2b clinical results for its investigational peptide therapy efinopegdutide (MK-6024) in the treatment of MASH. The study met its primary endpoint: after 52 weeks of treatment, the proportion of patients achieving MASH resolution without worsening of liver fibrosis was significantly higher in all efinopegdutide dose groups compared with the placebo group. Efinopegdutide is a once-weekly subcutaneous GLP-1/glucagon dual receptor agonist designed to regulate energy metabolism and reduce liver fat accumulation by simultaneously activating GLP-1 and glucagon receptors, while exploring potential improvements in liver inflammation and fibrosis.
Comments